source
- FDA grants three-month extension for Capricor’s Duchenne therapy deramiocel, sets new action date Nov 22The U.S. Food and Drug Administration has given Capricor Therapeutics a three‑month extension to review additional data for its Duchenne muscular dystrophy cell therapy, deramiocel. The agency has…
- Qiagen names Jonathan M. Pratt as new chief executive after nine-month searchQiagen announced that Jonathan M. Pratt will take over as chief executive, ending a nine‑month search for a successor. Pratt arrives from Filtration Group, where he served as president and CEO. He…